[HTML] cell.com

[HTML][HTML] Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer

L Liu, Y Wang, L Miao, Q Liu, S Musetti, J Li, L Huang - Molecular Therapy, 2018 - cell.com
Triple negative breast cancer (TNBC), which constitutes 10%–20% of all breast cancers, is
associated with aggressive progression, a high rate of metastasis, and poor prognosis. The …
被引用次数：296 相关文章

Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.

L Liu, Y Wang, L Miao, Q Liu, S Musetti… - Molecular Therapy: the …, 2017 - europepmc.org
Triple negative breast cancer (TNBC), which constitutes 10%–20% of all breast cancers, is
associated with aggressive progression, a high rate of metastasis, and poor prognosis. The …
[HTML] cell.com

[HTML][HTML] Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer

L Liu, Y Wang, L Miao, Q Liu, S Musetti, J Li, L Huang - Molecular Therapy, 2018 - cell.com
Triple negative breast cancer (TNBC), which constitutes 10%–20% of all breast cancers, is
associated with aggressive progression, a high rate of metastasis, and poor prognosis. The …
[HTML] nih.gov

[HTML][HTML] Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer

L Liu, Y Wang, L Miao, Q Liu, S Musetti, J Li… - Molecular …, 2018 - ncbi.nlm.nih.gov
Triple negative breast cancer (TNBC), which constitutes 10%–20% of all breast cancers, is
associated with aggressive progression, a high rate of metastasis, and poor prognosis. The …

Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer

L Liu, Y Wang, L Miao, Q Liu… - … therapy: the journal …, 2018 - pubmed.ncbi.nlm.nih.gov
Triple negative breast cancer (TNBC), which constitutes 10%-20% of all breast cancers, is
associated with aggressive progression, a high rate of metastasis, and poor prognosis. The …
[HTML] sciencedirect.com

[HTML][HTML] Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer

L Liu, Y Wang, L Miao, Q Liu, S Musetti, J Li, L Huang - Molecular Therapy, 2018 - Elsevier
Triple negative breast cancer (TNBC), which constitutes 10%–20% of all breast cancers, is
associated with aggressive progression, a high rate of metastasis, and poor prognosis. The …

Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.

L Liu, Y Wang, L Miao, Q Liu, S Musetti… - Molecular Therapy: the …, 2017 - europepmc.org
Triple negative breast cancer (TNBC), which constitutes 10%–20% of all breast cancers, is
associated with aggressive progression, a high rate of metastasis, and poor prognosis. The …